According to a RNCOS research report, “Booming Global Obesity Drug Market”, increasing prevalence of obesity and high unmet needs are driving the US to become one of the most potential markets for obesity drugs.
As per our analysis, the increasing rate of sedentary lifestyles and intake of high calorie food is taking its toll on the health of Americans. In 2007, around 207 Million people living in the US were classified as either overweight or obese. Out of these, more than 100 Million were found to be clinically obese. The figures of overweight and obesity are expected to reach 223 Million by 2012. The increasing prevalence of obesity in the country will in turn raise the prevalence of a number of lifestyle disorders such as diabetes, hypertension and dementia etc to catastrophic levels.
This pathetic condition is not only ringing alarm bells for the healthcare officials, but is also providing leveled field for obesity drug manufacturers. Americans spend around US$ 60 Billion annually on weight loss products. But no product available in the market has been able to provide the desired weight loss with an acceptable safety profile. Obesity drugs that are presently available in the market either suffer from serious side effects or just fail to provide the desired weight loss. More than 30 drugs, however, are undergoing various phase of clinical development wih three drugs in Phase-III development. Thus, any obesity drug if successfully launched in the market and if found to posses desired characteristics can lead to billions of dollars of revenues in no time, says the report.
“Booming Global Obesity Drug Market” is an extensive and objective analysis on the global market for obesity drugs. It investigates both the past and current trends in the global obesity market, and outlines the future trends shaping it up. It comprehensively assesses the performance of drugs, both on the market and in developing stage.
Based on various present and future indicators, the report evaluates future outlook and performance of key products in the industry. It can thus give valuable information for manufacturers/investors preparing to enter in the market for obesity drugs.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM166.htm
Check DISCOUNTED REPORTS on: http://www.rncos.com
About RNCOS:
RNCOS, incorporated in the year 2002, is an industry research firm. We are a team of industry experts who analyze data collected from credible sources. We provide industry insights and analysis that helps corporations to take timely and accurate business decision in today’s globally competitive environment.
